Maria Wiscovitch Guzman, MD
Pain Medicine · Hato Rey, PRNPI 1316023294
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 303 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 303 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$1K
- Amneal Pharmaceuticals LLC$1K
- EMD Serono, Inc.$753
- AbbVie$697
- Biogen$608
- AstraZeneca$490
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$1061%
- Food & beverage$7,87698%
- Education$931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 88 | $1,415 |
| Amneal Pharmaceuticals LLC | 71 | $1,339 |
| EMD Serono, Inc. | 9 | $753 |
| AbbVie | 18 | $697 |
| Biogen | 15 | $608 |
| AstraZeneca(2 entities) | 7 | $490 |
| PBG Puerto Rico LLC | 17 | $317 |
| UCB, Inc. | 6 | $296 |
| Sanofi | 12 | $277 |
| Amgen(2 entities) | 3 | $264 |
| Biohaven Pharmaceuticals, Inc. | 13 | $247 |
| E.r. Squibb & Sons, L.L.C. | 6 | $185 |
| Eli Lilly Export S.A. Puerto Rico Branch | 6 | $142 |
| Eisai Inc. | 1 | $125 |
| Banner Life Sciences, LLC | 1 | $125 |
| Sunovion Pharmaceuticals Inc. | 9 | $123 |
| Acorda Therapeutics, Inc | 1 | $117 |
| Greenwich Biosciences, Inc. | 1 | $110 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $106 |
| Lilly USA, LLC | 1 | $97 |
| Adamas Pharmaceuticals, Inc. | 4 | $65 |
| ANI Pharmaceuticals, Inc. | 3 | $47 |
| Medtronic | 1 | $46 |
| Novartis | 2 | $35 |
| Pfizer Pharmaceuticals LLC | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,075 in reported general payments places this provider in the 85th percentile of 46 pain medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 82 | $500,052 |
| Emgality PenGalcanezumab-Gnlm | 155 | $110,696 |
| UbrelvyUbrogepant | 78 | $96,233 |
| Rivastigmine | 416 | $89,380 |
| CopaxoneGlatiramer Acetate | 12 | $82,976 |
| Nurtec OdtRimegepant Sulfate | 46 | $69,511 |
| Galantamine ErGalantamine Hbr | 558 | $68,757 |
| RytaryCarbidopa/Levodopa | 114 | $58,952 |
| Memantine Hcl ErMemantine Hcl | 331 | $55,235 |
| Galantamine Hbr | 294 | $41,298 |
| Pregabalin | 1,014 | $30,583 |
| AptiomEslicarbazepine Acetate | 11 | $28,304 |
| NeuproRotigotine | 21 | $27,378 |
| Gabapentin | 1,571 | $25,139 |
| Donepezil Hcl | 720 | $23,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $1,415 | $500,05282 claims |
| AbbVieUbrelvy, Savella | $697 | $106,28698 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $22 | $82,97612 claims |
| Amneal Pharmaceuticals LLCRytary | $1,339 | $58,952114 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $123 | $28,30411 claims |
| UCB, Inc.Neupro | $296 | $27,37821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 46 pain medicine providers in Puerto Rico.
Other pain medicine in Hato Rey
- Eduardo IbarraAibonito$329K
- Jose Cruz CesteroCoto Laurel$196K
- Carlos Buxo TiradoSan Juan$64K
- Jose Carlo IzquierdoSan Juan$49K
- Francisco Lebron-ArzonBayamon$32K
- Jocelin Jones MolinaManati$5K
- Luis ArangurenCaguas$3K
- Francisco Irizarry RiveraPonce$2K
- Andres Melendez-DedosSan Juan$1K
- Jean Gallardo-VarelaSan Juan$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.